PRAME/OIP4 Peptide Pool, human

One unit allows the stimulation of 2,5 x 10⁸ cells.

You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

Gene:	PRAME
Delivery:	1-3 days
Amount:	15 nmol/peptide
Counter Ion:	TFA
Protein:	Melanoma antigen preferentially expressed in tumors
UniProt Id:	P78395
Species:	Human
Application :	T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication :	Cancer
Amount/Aliquote :	15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 10⁸ cells

Protocols and Tips

Handling peptides

Data sheets

Safety data sheet poly peptides:

Do you have any questions concerning this product?

Thelen M, Keller D, Lehmann J, et al.: Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells. Journal for ImmunoTherapy of Cancer 2022;10:e005200. doi: 10.1136/jitc-2022-005200

€228.00*

Prices excl. VAT plus shipping costs

Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.

Product number: LB01686

Similar Items

PRAME 100-108 (HLA-A*02:01) ( VLDGLDVLL )

The PRAME 100-108 peptide with the amino acid sequence VLDGLDVLL is a linear epitope (epitope ID 869501) derived from the Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395). It is used to stimulate human Prame (100-108)-specific CD8+T cells. PRAME belongs to the cancer/testis antigens in Homo sapiens. This antigen is notably overexpressed in various solid tumors, including melanoma, epithelial ovarian cancer, multiple sarcoma subtypes, and non-small cell lung cancer, while its expression in healthy tissues is mostly restricted to the testes. The PRAME 100-108 (VLDGLDVLL) epitope is presented by the MHC class I HLA-A*02:01 allele and was initially identified by Kessler et al. in 2001. In their studies, they demonstrated that cytotoxic T lymphocytes, which recognize this high-affinity binding epitope, could specifically target and lyse melanoma, lung, mammary, renal cell and cervical cancer cell lines.

From €63.50*

Details

PRAME 300–309 (HLA-A*02:01) ( ALYVDSLFFL )

ALYVDSLFFL is a linear peptidic epitope (epitope ID225231) studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human), tested in T cell assays. Antigen Peptide PRAME 300–309 (HLA-A*02:01) ALYVDSLFFL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €63.50*

Details

PRAME/OIP4 Peptide Pool, human

Pool of 125 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (UniProt ID: P78395) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression

€228.00*

PRAME 425-433 (HLA-A*02:01) ( SLLQHLIGL )

PRAME 425-433 (SLLQHLIGL) is a linear peptidic epitope (epitope ID 459114) studied as part of Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395), a cancer/testis antigen from Homo sapiens. PRAME is highly expressed in several solid tumors such as melanoma, epithelial ovarian cancer, multiple sarcoma subtypes and non-small cell lung cancer, while in healthy tissue it is almost exclusively restricted to the testicles. Therefore, it is a promising target for adoptive T cell therapies. PRAME 425-433 (SLLQHLIGL) was first described by Kessler et al. in 2001. In their experiments, cytotoxic T lymphocytes recognizing the high affinity binding, HLA-A*0201–restricted PRAME epitope specifically lysed melanoma, renal cell, lung, mammary, and cervical carcinoma cell lines.

From €63.50*

Details